OM Pemfailan SEC - Outset Medical, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

CIK

1484612

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Outset Medical, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

August 7, 2025	EX-10.3	Offer Letter between Outset Medical, Inc. and Renee Gaeta, dated as of May 31, 2025 Exhibit 10.3 May 31, 2025 Renee Gaeta Sent via email Dear Renee, On behalf of Outset Medical, Inc. (the “Company”), I am pleased to extend to you this conditional offer of employment in the position of Chief Financial Officer reporting directly to Leslie Trigg, Chair and Chief Executive Officer. This letter agreement sets forth the terms and conditions of your employment with the Company from and
August 7, 2025	EX-10.2	Outset Medical, Inc. Employee Stock Purchase Plan, as amended and restated Exhibit 10.2 Outset Medical, Inc. Employee Stock Purchase Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Amended and Restated, Effective April 9, 2025 Approved by the Stockholders: June 2, 2025 (In Respect Of Amendment 2025-1) Amended and Restated, Effective August 6, 2025 Termination Date: September 2, 2030 1. Purpose. The purpose of the
August 7, 2025	EX-10.1	Outset Medical, Inc. 2020 Equity Incentive Plan, as amended and restated Exhibit 10.1 Outset Medical, Inc. 2020 Equity Incentive Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Amended and Restated, Effective March 20, 2025 Approved by the Stockholders: June 2, 2025 (In Respect Of Amendment 2025-1) Amended and Restated, Effective August 6, 2025 Termination Date: September 2, 2030 I. Introduction 1.1 Purposes. Th
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
August 6, 2025	EX-99.1	Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization Company raises 2025 revenue guidance to a range of $122 million to $126 million Exhibit 99.1 Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization Company raises 2025 revenue guidance to a range of $122 million to $126 million San Jose, CA – Aug. 6, 2025 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and comple
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Outset Medical, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 5, 2025	S-8	As filed with the Securities and Exchange Commission on June 5, 2025 As filed with the Securities and Exchange Commission on June 5, 2025 Registration No.
June 5, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par v
June 3, 2025	EX-99.1	Outset Medical Appoints Renee Gaeta as Chief Financial Officer Exhibit 99.1 Outset Medical Appoints Renee Gaeta as Chief Financial Officer San Jose, CA June 3, 2025 - Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finan
June 3, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 29, 2025	EX-1.01	Conflict Minerals Report of Outset Medical, Inc. for the reporting period from January 1, 2024 to December 31, 2024 Exhibit 1.01 Conflict Minerals Report of Outset Medical, Inc. for the reporting period from January 1, 2024 to December 31, 2024 Introduction This Conflict Minerals Report (the “Report”) of Outset Medical, Inc. (“Outset”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for calendar year 2024 (the “Reporting Period”).
May 29, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Outset Medical, Inc. (Exact name of the registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Outset Medical, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification No.) 3052 Orchard Drive, San Jose, California 95134 (Address of principal ex
May 14, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 14, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 14, 2025	EX-99.1	Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors Exhibit 99.1 Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors San Jose, CA May 14, 2025 - Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O’Boyle to its Board of Directors and as chai
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
May 8, 2025	EX-10.1	Outset Medical, Inc. 2020 Equity Incentive Plan, as amended and restated Outset Medical, Inc. 2020 Equity Incentive Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Amended and Restated, Effective March 20, 2025 Termination Date: September 2, 2030 I. Introduction 1.1 Purposes. The purposes of the Outset Medical, Inc. 2020 Equity Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockhol
May 8, 2025	EX-10.2	Outset Medical, Inc. Employee Stock Purchase Plan, as amended and restated Outset Medical, Inc. Employee Stock Purchase Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Termination Date: September 2, 2030 (Amended and Restated, Effective April 9, 2025) 1. Purpose. The purpose of the Outset Medical, Inc. Employee Stock Purchase Plan (this “Plan”) is to provide eligible Employees of the Company and Participating Subs
May 7, 2025	EX-99.1	Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined Exhibit 99.1 Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined San Jose, CA – May 7, 2025 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended M
May 7, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File N
April 11, 2025	DEF 14A	Annual Meeting Information Board and Corporate Governance Matters Director Compensation EXECUTIVE COMPENSATION Equity Plan Information Stock Ownership Audit Matters Additional Information APPENDIX A: NON-GAAP RECONCILIATIONS APPENDIX B: PROPOSED AMEN Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 11, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 OUTSET MEDICAL, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 OUTSET MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission Fil
March 20, 2025	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Outset Medical, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OUTSET MEDICAL, INC. Outset Medical, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: FIRST: The name of the Corporation is Outset Medical, Inc. The Corporation was originally incorporate
March 18, 2025	EX-99.1	Outset Medical Announces One-for-Fifteen Reverse Stock Split Exhibit 99.1 Outset Medical Announces One-for-Fifteen Reverse Stock Split San Jose, CA March 18, 2025 — Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced a one-for-fifteen reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, pa
March 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 OUTSET MEDICAL, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 OUTSET MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission Fil
March 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 OUTSET MEDICAL, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 OUTSET MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission File
March 11, 2025	EX-3.1	Certificate of Correction of the Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock EX-3.1 Exhibit 3.1 CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK OF OUTSET MEDICAL, INC. Outset Medical, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. The name of the Corporation
March 6, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
February 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par v
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-19.1	Outset Medical, Inc. Insider Trading Policy Exhibit 19.1 Insider Trading Policy Approved by the Board of Directors Effective on September 15, 2020, as Revised on April 25, 2023 Introduction This policy determines acceptable transactions in the securities of Outset Medical, Inc. (the “Company” or “Outset”) by our employees and directors. During the course of your employment or directorship with the Company, you may receive important informat
February 28, 2025	424B3	215,835,000 Shares of Common Stock Offered by the Selling Stockholders 424B3 Table of Contents Filed Pursuant to Rule 424B3 Registration No. 333-284902 PROSPECTUS 215,835,000 Shares of Common Stock Offered by the Selling Stockholders Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis up to (i) 215,835,000 shares of our common stock, par value $0.001 per share issuable upon the conversion
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical,
February 26, 2025	CORRESP	OUTSET MEDICAL, INC. 3052 Orchard Dr. San Jose, CA 954134 February 26, 2025 OUTSET MEDICAL, INC. 3052 Orchard Dr. San Jose, CA 954134 669-231-8200 February 26, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Nicholas O’Leary Re: Outset Medical, Inc. Registration Statement on Form S-3 File No. 333-284902 Acceleration Request Requested Date: February 28, 2025 Requested Ti
February 26, 2025	S-3/A	As filed with the Securities and Exchange Commission on February 26, 2025. Registration No. 333-284902 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT As filed with the Securities and Exchange Commission on February 26, 2025. Registration No. 333-284902 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OUTSET MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 20-0514392 (State or other jurisdiction of incorporation
February 26, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
February 26, 2025	EX-99.1	Outset Medical, Inc. Index to Financial Statements Page Reports of Independent Registered Public Accounting Firm 2 Balance Sheets 6 Statements of Operations 7 Statements of Comprehensive Loss 8 Statements of Stockholders’ Equity 9 Statements of Cash EX-99.1 Exhibit 99.1 Outset Medical, Inc. Index to Financial Statements Page Reports of Independent Registered Public Accounting Firm 2 Balance Sheets 6 Statements of Operations 7 Statements of Comprehensive Loss 8 Statements of Stockholders’ Equity 9 Statements of Cash Flows 10 Notes to Financial Statements 12 1 Report of Independent Registered Public Accounting Firm To the Stockholders and Board
February 19, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
February 19, 2025	EX-99.1	Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results San Jose, CA – February 19, 2025 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End High
February 13, 2025	EX-FILING FEES	Calculation of Registration Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) OUTSET MEDICAL, INC.
February 13, 2025	EX-4.4	Form of Indenture (relating to the debt securities registered hereby). Exhibit 4.4 OUTSET MEDICAL, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) 102 (c)(2) 102 (e) 102 Sec. 315(b) 601 Sec. 316(a) (last sentence) 101 (“Outstanding”) (a)(1)(A) Article 5 (a)(1)(B) Article 5 (b) Article 5 (c) 104(c) Sec. 317(a)
February 13, 2025	S-3	As filed with the Securities and Exchange Commission on February 13, 2025. Table of Contents As filed with the Securities and Exchange Commission on February 13, 2025.
February 4, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary
January 24, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary P
January 24, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 23, 2025 Date of Report (Date of earliest event reported) Outset Medical, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission File N
January 24, 2025	EX-3.1	Amendment No. 1 To Amended and Restated Bylaws of Outset Medical, Inc., dated January 23, 2025 Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF OUTSET MEDICAL, INC. The Amended and Restated Bylaws (the “Bylaws”) of Outset Medical, Inc., a Delaware corporation (the “Corporation”), are hereby amended as set forth in this Amendment No. 1: 1. Voting. Subsection (a) of Section 1.7 of the Bylaws is hereby amended and restated to read in its entirety as follows: “(a) Matters Other Tha
January 8, 2025	EX-3.1	Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock Exhibit 3.1 Execution Version OUTSET MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Outset Medical, Inc., a Delaware corporation (the “Corporation”), that the following resolution was du
January 8, 2025	EX-4.1	Warrant Certificate, dated January 8, 2025, issued by Outset Medical, Inc. to Perceptive Credit Holdings IV, LP Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUC
January 8, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 7, 2025 Date of Report (Date of earliest event reported) Outset Medical, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission File Nu
January 6, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2025 Date of Report (Date of earliest event reported) Outset Medical, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission File Nu
January 6, 2025	EX-10.4	Credit Agreement and Guaranty, dated as of January 3, 2025, by and among Outset Medical, Inc. as the borrower and Perceptive Credit Holdings IV, LP, as the initial lender and the administrative agent Exhibit 10.4 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version CREDIT AGREEMENT AND GUARANTY dated as of January 3, 2025 by and among OUTSET MEDICAL, INC. as the Borrower, THE SUBSIDIARY
January 6, 2025	EX-10.3	Form of Registration Rights Agreement, dated as of January 3, 2025 between Outset Medical, Inc. and the Investors Exhibit 10.3 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 3, 2025, is entered into by and among Outset Medical, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capit
January 6, 2025	EX-99.1	Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and Healthcare Institutional Investors Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in Prior Debt Reports Unaudited F Exhibit 99.1 Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and Healthcare Institutional Investors Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in Prior Debt Reports Unaudited Fourth-Quarter Revenue of $29 million and 2024 Revenue of $113 million SAN JOSE, Calif.—Jan. 6, 2025— Outset Medical, Inc. (Nasdaq: OM) (“
January 6, 2025	EX-10.1	Form of Securities Purchase Agreement, dated as of January 3, 2025 between Outset Medical, Inc. and certain of the Investors Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT BY AND AMONG OUTSET MEDICAL, INC., AND THE PURCHASERS AS SET FORTH HEREIN JANUARY 3, 2025 TABLE OF CONTENTS 1. Definitions 2 2. Purchase and Sale of Securities 4 2.1 Purchase and Sale 4 2.2 Closing 5 3. Representations and Warranties of the Company 6 3.1 Organization and Power; No Subsidiaries 6 3.2 Capitalization 6 3.3 Registration Ri
January 6, 2025	EX-10.2	Form of Securities Purchase Agreement, dated as of January 3, 2025 between Outset Medical, Inc. and certain members of management and certain directors Exhibit 10.2 Execution Version SECURITIES PURCHASE AGREEMENT BY AND AMONG OUTSET MEDICAL, INC., AND THE PURCHASERS AS SET FORTH HEREIN JANUARY 3, 2025 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 6 3.1 Organization and Power; No Subsidiaries 6 3.2 Capitalization 6 3.3 Registration Righ
November 12, 2024	SC 13G/A	OM / Outset Medical, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 OMSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) OUTSET MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 690145107 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriat
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
November 6, 2024	EX-99.1	Outset Medical Reports Third Quarter 2024 Financial Results Exhibit 99.1 Outset Medical Reports Third Quarter 2024 Financial Results San Jose, CA – November 6, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2024. “During the quarter, we made si
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission F
September 27, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
September 10, 2024	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II 3 d846677dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated September 10, 2024 in connection with their beneficial ownership of Outset Medical, Inc. Each of Columbia Acorn Fund, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC a
September 10, 2024	EX-99.I	to Schedule 13G EX-99.I 2 d846677dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –
September 10, 2024	SC 13G/A	OM / Outset Medical, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #2 Under the Securities and Exchange Act of 1934 Outset Medical, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) August 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
September 5, 2024	SC 13G/A	OM / Outset Medical, Inc. / JPMORGAN CHASE & CO - FILING OUTSET MEDICAL, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 05)* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) August 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
August 23, 2024	SC 13G	OM / Outset Medical, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OUTSET MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 690145107 (CUSIP Number) AUGUST 19, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
August 16, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fi
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
August 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Outset Medical, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 7, 2024	EX-99.1	Outset Medical Reports Second Quarter 2024 Financial Results Exhibit 99.1 Outset Medical Reports Second Quarter 2024 Financial Results San Jose, CA – August 7, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2024. “During the quarter, the number of t
May 30, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 29, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Outset Medical, Inc. (Exact name of the registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Outset Medical, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification No.) 3052 Orchard Drive, San Jose, California 95134 (Address of principal ex
May 29, 2024	EX-1.01	Conflict Minerals Report of Outset Medical, Inc. for the reporting period from January 1, 2023 to December 31, 2023 Exhibit 1.01 Conflict Minerals Report of Outset Medical, Inc. for the reporting period from January 1, 2023 to December 31, 2023 Introduction This Conflict Minerals Report (the “Report”) of Outset Medical, Inc. (“Outset”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for calendar year 2023 (the “Reporting Period”).
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
May 9, 2024	EX-10.2	Amendment to Manufacturing Services Agreement by and between TACNA Services, Inc. and Outset Medical, Inc. effective as of February 12, 2024 Exhibit 10.2 *Portions of this exhibit have been excluded because it is both (i) not material and (ii) the type of information that the Registrant both customarily and actually treats as private and confidential. TACNA Services, Inc. MANUFACTURING SERVICE AGREEMENT Client: Outset Medical ANNEX "A" (Service Fee Schedule) Effective February 12, 2024 Number of Employees Total Paid Hours Weekly Fee Pe
May 8, 2024	EX-99.1	Outset Medical Reports First Quarter 2024 Financial Results Exhibit 99.1 Outset Medical Reports First Quarter 2024 Financial Results San Jose, CA – May 8, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024. “With our recent 510(k) clearance for Ta
May 8, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File N
May 6, 2024	EX-99.1	Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance Exhibit 99.1 Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance SAN JOSE, Calif. – May 6, 2024 - Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with
May 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Outset Medical, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File N
April 11, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 11, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 10, 2024	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II 3 d824955dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated April 10, 2024 in connection with their beneficial ownership of Outset Medical, Inc. Each of Columbia Acorn Fund, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC autho
April 10, 2024	EX-99.I	to Schedule 13G EX-99.I 2 d824955dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –
April 10, 2024	SC 13G/A	OM / Outset Medical, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Outset Medical, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) March 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f
March 13, 2024	EX-99.1	Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors Exhibit 99.1 Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors San Jose, CA March 13, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its boa
March 13, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
February 22, 2024	S-8	As filed with the Securities and Exchange Commission on February 21, 2024 As filed with the Securities and Exchange Commission on February 21, 2024 Registration No.
February 22, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par v
February 21, 2024	EX-10.11	Form of Amended and Restated Change in Control and Severance Agreement for Chief Executive Officer Exhibit 10.11 OUTSET MEDICAL, Inc. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Outset Medical, Inc. (the “Company”) and Leslie Trigg (the “Executive”), effective as of [ ], 2024 (the “Effective Date”). The Company and the Executive entered into a Change in Control and Severance
February 21, 2024	EX-97.1	Outset Medical, Inc. Policy on Recoupment of Incentive Compensation Exhibit 97.1 OUTSET MEDICAL, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. This P
February 21, 2024	EX-99.1	Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results San Jose, CA – February 21, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023. F
February 21, 2024	EX-10.12	Form of Amended and Restated Change in Control and Severance Agreement for non-Chief Executive Officer executive officers Exhibit 10.12 OUTSET MEDICAL, Inc. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Outset Medical, Inc. (the “Company”) and [ ] (the “Executive”), effective as of [], 2024 (the “Effective Date”). The Company and the Executive entered into a Change in Control and Severance Agreement,
February 21, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
February 21, 2024	EX-10.25	First Amendment to Loan and Security Agreement by and among SLR Investment Corp., as collateral agent, the lenders party thereto and Outset Medical, Inc. dated as of December 11, 2023 Exhibit 10.25 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of December 11, 2023 (the “Amendment Effective Date”), is made among SLR Investment Corp., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such capacity, together with its succe
February 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical,
February 21, 2024	EX-10.4	Outset Medical, Inc. 2020 Equity Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.4 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on February 21, 2024). Exhibit 10.4 Outset Medical, Inc. 2020 Equity Incentive Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Amended and Restated : January 1, 2024 Termination Date: September 2, 2030 I. Introduction 1.1 Purposes. The purposes of the Outset Medical, Inc. 2020 Equity Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s sto
February 14, 2024	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II 3 d743484dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2024 in connection with their beneficial ownership of Outset Medical, Inc. Each of Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameriprise F
February 14, 2024	EX-99.I	to Schedule 13G EX-99.I 2 d743484dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –
February 14, 2024	SC 13G	OM / Outset Medical, Inc. / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Outset Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: This
February 13, 2024	SC 13G/A	OM / Outset Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01637-outsetmedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Outset Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 690145107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designat
February 13, 2024	SC 13G/A	OM / Outset Medical, Inc. / Bellevue Group AG - SC 13G/A Passive Investment SC 13G/A 1 d766976dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OUTSET MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designat
January 23, 2024	SC 13G/A	OM / Outset Medical, Inc. / JPMORGAN CHASE & CO - FILING OUTSET MEDICAL, INC. Passive Investment SC 13G/A 1 OutsetMedicalInc.htm FILING OUTSET MEDICAL, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of
January 8, 2024	EX-99.2	Outset Medical Investor Presentation January 2024 Outset Medical Investor Presentation January 2024 Forward-looking statements and non-GAAP information This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws.
January 8, 2024	EX-99.1	Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance Exhibit 99.1 Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance San Jose, CA January 8, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal ye
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Outset Medical, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Outset Medical, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fi
December 11, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
November 7, 2023	EX-99.2	Outset Medical Investor Presentation November 2023 Outset Medical Investor Presentation November 2023 Forward-looking statements and non-GAAP information This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws.
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission F
November 7, 2023	EX-99.1	Outset Medical Reports Third Quarter 2023 Financial Results Reiterates Updated 2023 Revenue Guidance of Approximately $130 Million Exhibit 99.1 Outset Medical Reports Third Quarter 2023 Financial Results Reiterates Updated 2023 Revenue Guidance of Approximately $130 Million San Jose, CA – November 7, 2023 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the
October 12, 2023	EX-99.1	Outset Medical Reports Preliminary Third Quarter 2023 Financial Results Conference Call Scheduled for 4:30 p.m. ET Exhibit 99.1 Outset Medical Reports Preliminary Third Quarter 2023 Financial Results Conference Call Scheduled for 4:30 p.m. ET San Jose, CA – Oct. 12, 2023 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023. Preliminary revenue for the third quar
October 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 Outset Medical, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission F
September 8, 2023	SC 13G/A	OM / Outset Medical Inc / JPMORGAN CHASE & CO - FILING OUTSET MEDICAL, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) August 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
August 2, 2023	EX-99.1	Outset Medical Reports Second Quarter 2023 Financial Results Sequential Revenue Growth of 8%, Ninth Consecutive Quarter of Gross Margin Expansion Announces Shipment Pause of TabloCart with Prefiltration Pending 510(k) Clearance Reiterates 2023 Revenu Exhibit 99.1 Outset Medical Reports Second Quarter 2023 Financial Results Sequential Revenue Growth of 8%, Ninth Consecutive Quarter of Gross Margin Expansion Announces Shipment Pause of TabloCart with Prefiltration Pending 510(k) Clearance Reiterates 2023 Revenue Range of $144 Million to $150 Million San Jose, CA – August 2, 2023 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a
August 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fil
July 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 Outset Medical, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
June 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Outset Medical, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 31, 2023	EX-1.01	Conflict Minerals Report of Outset Medical, Inc. for the reporting period from January 1, 2022 to December 31, 2022 Exhibit 1.01 Conflict Minerals Report of Outset Medical, Inc. for the reporting period from January 1, 2022 to December 31, 2022 Introduction This Conflict Minerals Report (the “Report”) of Outset Medical, Inc. (“Outset”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for calendar year 2022 (the “Reporting Period”).
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Outset Medical, Inc. (Exact name of the registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Outset Medical, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification No.) 3052 Orchard Drive, San Jose, California 95134 (Address of principal ex
May 16, 2023	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nabeel Ahmed, John L.
May 16, 2023	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nabeel Ahmed, John L.
May 16, 2023	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nabeel Ahmed, John L.
May 16, 2023	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nabeel Ahmed, John L.
May 16, 2023	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nabeel Ahmed, John L.
May 16, 2023	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nabeel Ahmed, John L.
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q d UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
May 3, 2023	EX-99	Outset Medical Reports First Quarter 2023 Financial Results Increases Revenue and Gross Margin Guidance for 2023 Exhibit 99.1 Outset Medical Reports First Quarter 2023 Financial Results Increases Revenue and Gross Margin Guidance for 2023 San Jose, CA – May 3, 2023 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended Mar
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Outset Medical, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File N
April 13, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 14, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par v
February 14, 2023	S-8	As filed with the Securities and Exchange Commission on February 13, 2023 As filed with the Securities and Exchange Commission on February 13, 2023 Registration No.
February 14, 2023	EX-99.A	Joint Filing Statement EX-99.A 2 d439025dex99a.htm EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. Bellevue Group AG Date: February 14, 2023 By: /s/ Michael Hutter Signatory Authority Name: Michael Hutter Title: Chief Financial Officer Date: February 14, 2023 By: /s/
February 14, 2023	SC 13G	OM / Outset Medical Inc / Bellevue Group AG - SC 13G Passive Investment SC 13G 1 d439025dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OUTSET MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w
February 14, 2023	SC 13G/A	OM / Outset Medical Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d9sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Outset Medical, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December
February 14, 2023	SC 13G/A	OM / Outset Medical Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Outset Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Outset Medical, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
February 13, 2023	EX-99	Outset Medical Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Outset Medical Reports Fourth Quarter and Full Year 2022 Financial Results San Jose, CA – February 13, 2023 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2022. R
February 13, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical,
February 9, 2023	SC 13G/A	OM / Outset Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01604-outsetmedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Outset Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 690145107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designa
January 25, 2023	SC 13G/A	OM / Outset Medical Inc / JPMORGAN CHASE & CO - FILING OUTSET MEDICAL, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
January 9, 2023	EX-99.2	Outset Medical Investor Presentation January 2023 Outset Medical Investor Presentation January 2023 Forward-looking statements This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws.
January 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 9, 2023	EX-99.1	Outset Medical Reports Expected Fourth Quarter and Full Year 2022 Revenue, Provides 2023 Revenue and non-GAAP Gross Margin Guidance Exhibit 99.1 Outset Medical Reports Expected Fourth Quarter and Full Year 2022 Revenue, Provides 2023 Revenue and non-GAAP Gross Margin Guidance San Jose, CA – January 9, 2023 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported expected revenue for the f
November 9, 2022	EX-10.2	Credit Agreement by and between Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL and Outset Medical, Inc. dated as of November 3, 2022 Exhibit 10.2 Portions of this exhibit have been excluded because it is both (i) not material and (ii) the type of information that the Registrant both customarily and actually treats as private and confidential. CREDIT AGREEMENT between OUTSET MEDICAL, INC. and such other Persons joined hereto as a Borrower from time to time, as Borrowers, with GEMINO HEALTHCARE FINANCE, LLC d/b/a SLR HEALTHCARE A
November 9, 2022	EX-10.3	Outset Medical, Inc. Employee Stock Purchase Plan, as amended and restated (incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022, filed with the Commission on November 9, 2022). Exhibit 10.3 Outset Medical, Inc. Employee Stock Purchase Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Termination Date: September 2, 2030 (Amended and Restated, Effective September 1, 2022) 1. Purpose. The purpose of the Outset Medical, Inc. Employee Stock Purchase Plan (this ?Plan?) is to provide eligible Employees of the Company and P
November 9, 2022	EX-10.1	Loan and Security Agreement by and between SLR Investment Corp., the lenders from time to time party thereto and Outset Medical, Inc. dated as of November 3, 2022 Exhibit 10.1 Portions of this exhibit have been excluded because it is both (i) not material and (ii) the type of information that the Registrant both customarily and actually treats as private and confidential. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of November 3, 2
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
November 8, 2022	EX-99.1	Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million Exhibit 99.1 Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million San Jose, CA ? November 8, 2022 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission F
November 4, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission F
November 4, 2022	EX-99.1	Outset Medical Secures Up To $300 Million in Debt Financing Exhibit 99.1 Outset Medical Secures Up To $300 Million in Debt Financing San Jose, CA ? November 4, 2022 - Outset Medical, Inc. (Nasdaq: OM)(?Outset?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it has entered into two senior secured credit facilities with investment affiliates managed by SLR Capital Pa
August 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
August 1, 2022	EX-99.1	Outset Medical Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST Exhibit 99.1 Outset Medical Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST San Jose, CA ? August 1, 2022 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost a
August 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fil
July 7, 2022	SC 13G/A	OM / Outset Medical Inc / JPMORGAN CHASE & CO - FILING OUTSET MEDICAL, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
June 13, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
June 13, 2022	EX-99.1	Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST Exhibit 99.1 Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST San Jose, CA ? June 13, 2022 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?company?), today announced it has implemented a shipment hold on the distribution of its Tablo Hemodialys
June 1, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File N
May 4, 2022	EX-99.1	Outset Medical Reports First Quarter 2022 Financial Results Revenue Grows 33.3% to $30.6 million, Gross Margin expands 13.2 percentage points to 14.5% Year-over-Year Exhibit 99.1 Outset Medical Reports First Quarter 2022 Financial Results Revenue Grows 33.3% to $30.6 million, Gross Margin expands 13.2 percentage points to 14.5% Year-over-Year San Jose, CA ? May 4, 2022 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today repor
April 25, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fil
April 25, 2022	EX-99.1	Outset Medical Names Business Leader Dale E. Jones to Board of Directors Exhibit 99.1 Outset Medical Names Business Leader Dale E. Jones to Board of Directors San Jose, CA ? April 25, 2022 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset?), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. ?Dale brings more than 30 years of experience in building diverse and dynamic teams t
April 25, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 14, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) DEFA14A 1 om-defa14a20220414.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden
April 14, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) DEF 14A 1 om-def14a20220414.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident
February 23, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical,
February 23, 2022	S-8	As filed with the Securities and Exchange Commission on February 23, 2022 As filed with the Securities and Exchange Commission on February 23, 2022 Registration No.
February 23, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par v
February 23, 2022	EX-10.9	Outset Medical, Inc. 2020 Employee Stock Purchase Plan, as amended and restated Exhibit 10.9 Outset Medical, Inc. Employee Stock Purchase Plan Adopted By The Board Of Directors: September 2, 2020 Approved By The Stockholders: September 7, 2020 Termination Date: September 2, 2030 (Amended and Restated, Effective March 1, 2022) 1. Purpose. The purpose of the Outset Medical, Inc. Employee Stock Purchase Plan (this ?Plan?) is to provide eligible Employees of the Company and Parti
February 16, 2022	EX-99.2	Forward-looking statements and non-GAAP information This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact a Outset Medical Investor Presentation February 2022 Exhibit 99.2 Forward-looking statements and non-GAAP information This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking stateme
February 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2022 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
February 16, 2022	EX-99.1	Outset Medical Reports Fourth Quarter and Full Year 2021 Financial Results Record Annual Revenue of $102.6 Million; 105% Year-over-Year Growth Exhibit 99.1 Outset Medical Reports Fourth Quarter and Full Year 2021 Financial Results Record Annual Revenue of $102.6 Million; 105% Year-over-Year Growth San Jose, CA ? February 16, 2022 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial res
February 15, 2022	SC 13G/A	OM / Outset Medical Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Outset Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 690145 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 15, 2022	EX-99.1	AGREEMENT EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC
February 14, 2022	SC 13G	OM / Outset Medical Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Outset Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
February 14, 2022	SC 13G/A	OM / Outset Medical Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Outset Medical, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2021 Date of Event Which Requires
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Outset Medical, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the un
February 14, 2022	SC 13G/A	OM / Outset Medical Inc / D1 Capital Partners L.P. - OUTSET MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Outset Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 11, 2022	SC 13G/A	OM / Outset Medical Inc / WARBURG PINCUS LLC - WARBURG 13G-A Passive Investment SC 13G/A 1 warburg13ga.htm WARBURG 13G-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Outset Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check
February 10, 2022	SC 13G	OM / Outset Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01602-outsetmedicalinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Outset Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 690145107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to
January 26, 2022	SC 13G	OM / Outset Medical Inc / JPMORGAN CHASE & CO - FILING OUTSET MEDICAL, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
December 7, 2021	SC 13G/A	OM / Outset Medical Inc / Mubadala Investment Co PJSC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
November 3, 2021	EX-99.1	Outset Medical Reports Third Quarter 2021 Financial Results 2021 Revenue Guidance Range Elevated to $99 million to $101 million Exhibit 99.1 Outset Medical Reports Third Quarter 2021 Financial Results 2021 Revenue Guidance Range Elevated to $99 million to $101 million San Jose, CA ? November 3, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the thi
November 3, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission F
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
August 5, 2021	EX-99.2	Outset Medical Names Nabeel Ahmed as Chief Financial Officer Exhibit 99.2 Outset Medical Names Nabeel Ahmed as Chief Financial Officer San Jose, CA ? August 5, 2021 - Outset Medical, Inc. (Nasdaq: OM) (?Outset?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Nabeel Ahmed, currently serving as Outset?s Interim Chief Financial Officer, has transitioned to the permanen
August 5, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
August 5, 2021	EX-99.1	Outset Medical Reports Second Quarter 2021 Financial Results 2021 Revenue Guidance Range Updated to $97 million to $100 million Exhibit 99.1 Outset Medical Reports Second Quarter 2021 Financial Results 2021 Revenue Guidance Range Updated to $97 million to $100 million San Jose, CA ? August 5, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the secon
July 1, 2021	EX-99.1	Outset Medical Announces Departure of CFO and Appointment of Nabeel Ahmed as Interim CFO Reports Preliminary Results for Second Quarter 2021 Exhibit 99.1 Outset Medical Announces Departure of CFO and Appointment of Nabeel Ahmed as Interim CFO Reports Preliminary Results for Second Quarter 2021 San Jose, CA ? July 1, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Rebecca Chambers will step down
July 1, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
June 4, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 24, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
May 24, 2021	EX-99.1	Outset Medical Appoints MedTech Executive Katie Szyman to Board of Directors Exhibit 99.1 Outset Medical Appoints MedTech Executive Katie Szyman to Board of Directors SAN JOSE, Calif. ? May 24, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset?), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, today announced the appointment of Katie Szyman to its board of directors. Szyman, currently Corporate Vice Presiden
May 24, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 6, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc.
May 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File N
May 5, 2021	EX-99.1	Outset Medical Reports First Quarter 2021 Financial Results Exhibit 99.1 Outset Medical Reports First Quarter 2021 Financial Results San Jose, CA ? May 5, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset? or the ?Company?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2021. Recent Highlights ? Recorded net revenue
April 21, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 21, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 13, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 8, 2021 Outset Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation or organization)
April 13, 2021	EX-1.1	Underwriting Agreement dated April 8, 2021 Exhibit 1.1 OUTSET MEDICAL, INC. (a Delaware corporation) 5,944,859 Shares of Common Stock UNDERWRITING AGREEMENT Dated: April 8, 2021 OUTSET MEDICAL, INC. (a Delaware corporation) 5,944,859 Shares of Common Stock UNDERWRITING AGREEMENT April 8, 2021 Morgan Stanley & Co. LLC BofA Securities, Inc. Goldman Sachs & Co. LLC as Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 15
April 13, 2021	EX-99.2	Outset Medical Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Exhibit 99.2 Outset Medical Announces Closing of Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares April 13, 2021 SAN JOSE, Calif. ?(BUSINESS WIRE)? April 13, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the closing of i
April 13, 2021	EX-99.1	Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering EX-99.1 Exhibit 99.1 Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering April 9, 2021 SAN JOSE, Calif.—(BUSINESS WIRE)—Apr. 9, 2021—Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 2,500,0
April 12, 2021	424B4	5,944,859 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Number 333-255062 and 333-255141 PROSPECTUS 5,944,859 Shares Common Stock We are offering 2,500,000 shares of our common stock.
April 8, 2021	S-1MEF	- S-1MEF As filed with the Securities and Exchange Commission on April 8, 2021 Registration No.
April 6, 2021	CORRESP	- Via EDGAR Submission April 6, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
April 6, 2021	EX-1.1	Form of Underwriting Agreement EX-1.1 2 d149149dex11.htm EX-1.1 Exhibit 1.1 OUTSET MEDICAL, INC. (a Delaware corporation) [ ● ] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [ ● ], 2021 OUTSET MEDICAL, INC. (a Delaware corporation) [ ● ] Shares of Common Stock UNDERWRITING AGREEMENT [ ● ], 2021 Morgan Stanley & Co. LLC BofA Securities, Inc. Goldman Sachs & Co. LLC as Representatives of the several Underwriters c/o Morgan
April 6, 2021	S-1	Registration Statement - S-1 Table of Contents As filed with the Securities and Exchange Commission on April 6, 2021 Registration No.
April 6, 2021	CORRESP	- CORRESP 1 filename1.htm April 6, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tim Buchmiller Re: Outset Medical, Inc. Registration Statement on Form S-1 File No. 333-255062 Acceleration Request Requested Date: April 8, 2021 Requested Time: 4:00 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Ru
April 6, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2021 Outset Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation or organization)
April 6, 2021	EX-99.1	Outset Medical Announces Primary and Secondary Offering of Common Stock Exhibit 99.1 Outset Medical Announces Primary and Secondary Offering of Common Stock San Jose, CA ? April 6, 2021 ? Outset Medical, Inc. (Nasdaq: OM) (?Outset?), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of a proposed underwritten public offering of 2,500,000 shares of its common stock by O
March 25, 2021	DRSLTR	March 25, 2021 SIDLEY AUSTIN LLP 787 SEVENTH AVENUE NEW YORK, NY 10019 +1 212 839 5300 +1 212 839 5599 FAX AMERICA ? ASIA PACIFIC ? EUROPE RRYAN@SIDLEY.
March 25, 2021	DRS	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 Confidential draft submitted to the Securities and Exchange Commission on March 25, 2021. This draft registration statement has not been filed publicly with the Securities and Exch Table of Contents CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 Confidential draft submitted to the Securities and Exchange Commission on March 25, 2021. This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHAN
March 24, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fil
March 24, 2021	EX-99.1	Outset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors Exhibit 99.1 Outset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors SAN JOSE, Calif. – March 24, 2021 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), the medical technology company that pioneered the Tablo Hemodialysis System, a first-of-its-kind device to reduce the cost and complexity of dialysis, is strengthening its consumer focus with the appointment of Andrea
March 22, 2021	EX-10.5	Form of Stock Option Grant Notice and Option Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan Exhibit 10.5 OUTSET MEDICAL, INC. STOCK OPTION GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Outset Medical, Inc. (the ?Company?), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Optionholder an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). The Option is subject to
March 22, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical,
March 22, 2021	EX-10.6	Form of Restricted Stock Unit Award Grant Notice and Award Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan Exhibit 10.6 OUTSET MEDICAL, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Outset Medical, Inc. (the ?Company?), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Participant a restricted stock unit award relating to the number of restricted stock units set forth below (the ?Award
March 22, 2021	EX-10.8	Form of Performance Stock Unit Award Grant Notice and Award Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan Exhibit 10.8 OUTSET MEDICAL, INC. PERFORMANCE STOCK UNIT AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Outset Medical, Inc. (the ?Company?), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Participant a performance stock unit award relating to the target number of performance stock units set forth below (
March 22, 2021	EX-10.29	Amendment to Solicitation/Modification of Contract from ASPR-BARDA to Outset Medical, Inc., dated November 25, 2020 Exhibit 10.29 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENTS OF SOLICITATION/ MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00002 3. EFFECTIVE DATE SEE BLOCK 16C 4 REQUISITION / PURCHASE REQ. NO. OS268645 5. PROJECT NO (If applicable) 6. ISSUED
March 22, 2021	EX-10.30	Supply Agreement by and between Carlisle Interconnect Technologies, Inc. and Outset Medical, Inc., dated January 12, 2021 Exhibit 10.30 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. This SUPPLY AGREEMENT, the ?Agreement?) is entered into as of January 12, 2021 (the ?Effective Date?) by and between Carlisle Interconnect Technologies, Inc, headquartered at 100 Tensolite Drive, St. Augustine FL 32092 with manufacturing loca
March 22, 2021	EX-4.5	Description of Outset Medical, Inc.’s Securities Registered Pursuant to Section 12 of the Exchange Act Exhibit 4.5 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the capital stock of Outset Medical, Inc. (the ?Company,? ?we,? ?us,? and ?our?) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated registration rig
March 22, 2021	EX-10.7	Form of Restricted Stock Award Grant Notice and Award Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan Exhibit 10.7 OUTSET MEDICAL, INC. RESTRICTED STOCK AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Outset Medical, Inc. (the ?Company?), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Participant a restricted stock award relating to the number of restricted shares of Common Stock set forth below (the ?Awar
March 9, 2021	EX-99.1	Outset Medical Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Outset Medical Reports Fourth Quarter and Full Year 2020 Financial Results San Jose, CA – March 9, 2021 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights • Re
March 9, 2021	EX-99.2	This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact are forward-looking statements. In some cases, you ca Outset Medical Fourth Quarter & Full Year 2020 Earnings Call March 9, 2021 Exhibit 99.
March 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission File
February 22, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission
February 16, 2021	SC 13G/A	NUMBER OF OWNED BY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Outset Medical, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2020 Date of Event Which Requires
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Outset Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 16, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm216018d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Outset Medical, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Outset Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securit SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Outset Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 690145 107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 12, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) Outset Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 690145107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 11, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Outset Medical, Inc.
February 11, 2021	EX-99.A	JOINT FILING AGREEMENT CUSIP No. 69145107 SCHEDULE 13G Page 9 of 9 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 10, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.001 per share, of Outset Medical, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securi
January 12, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 Outset Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39513 20-0514392 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 12, 2021	EX-99.1	Outset Medical Appoints Karen Drexler to Board of Directors Healthcare Industry Veteran Brings Digital Health Expertise and Consumer-Centric Approach to Furthering Company’s Mission of Transforming Dialysis Treatment Exhibit 99.1 Outset Medical Appoints Karen Drexler to Board of Directors Healthcare Industry Veteran Brings Digital Health Expertise and Consumer-Centric Approach to Furthering Company’s Mission of Transforming Dialysis Treatment SAN JOSE, Calif. – Jan. 12, 2021 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and
December 3, 2020	424B4	4,000,000 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Number 333-251031 PROSPECTUS 4,000,000 Shares Common Stock Certain stockholders of Outset Medical, Inc.
November 30, 2020	CORRESP	- CORRESP November 30, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Suzanne Hayes Jeff Gabor Sasha Parikh Tracey Houser Re: Outset Medical, Inc. Registration Statement on Form S-1 File No. 333-251031 Acceleration Request Requested Date: December 2, 2020 Requested Time: 4:00 P.M., Eastern Time Ladies a
November 30, 2020	EX-99.1	Outset Medical Announces Secondary Offering of Common Stock EX-99.1 Exhibit 99.1 Outset Medical Announces Secondary Offering of Common Stock San Jose, CA – November 30, 2020 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of a proposed underwritten public offering of 4,000,000 shares of its common stock by c
November 30, 2020	S-1	As filed with the Securities and Exchange Commission on November 30, 2020. S-1 Table of Contents As filed with the Securities and Exchange Commission on November 30, 2020.
November 30, 2020	CORRESP	- Via EDGAR Submission November 30, 2020 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 30, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 30, 2020 Outset Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39513 20-0514392 (State or other jurisdiction of incorporation or organi
November 30, 2020	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 OUTSET MEDICAL, INC. (a Delaware corporation) [ ● ] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [ ● ], 2020 OUTSET MEDICAL, INC. (a Delaware corporation) [ ● ] Shares of Common Stock UNDERWRITING AGREEMENT [ ● ], 2020 BofA Securities, Inc. Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant
November 19, 2020	DRS	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 Confidential draft submitted to the Securities and Exchange Commission on November 18, 2020. This draft registration statement has not been filed publicly with the Securities and E Table of Contents CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 Confidential draft submitted to the Securities and Exchange Commission on November 18, 2020. This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXC
November 18, 2020	DRSLTR	- DRSLTR SIDLEY AUSTIN LLP 787 SEVENTH AVENUE NEW YORK, NY 10019 +1 212 839 5300 +1 212 839 5599 FAX AMERICA • ASIA PACIFIC • EUROPE RRYAN@SIDLEY.

OM / Outset Medical, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)